-- 据彭博社周一援引两位知情人士的消息报道,俄罗斯预计将以比欧洲价格低约38%的价格向中国出售天然气。 报道称,价格差距反映了莫斯科在2022年乌克兰战争后失去大部分欧洲买家后,议价能力的下降。 报道称,政府预测显示,今年中国天然气平均价格约为每千立方米258.80美元,远低于剩余欧洲买家的支付水平。 消息人士称,预计到2029年,对华天然气出口价格仍将大幅低于欧洲价格,价格差距虽会缩小,但仍将超过27%。 报道援引政府数据称,数据显示,去年俄罗斯对华天然气售价约为每千立方米248.7美元,同样比欧洲价格低38%以上。 报道援引国际文传电讯社的消息称,俄罗斯天然气工业股份公司首席执行官阿列克谢·米勒表示,价格差异反映了亚洲市场运输距离的缩短。报告指出,2022年乌克兰战争后,俄罗斯与欧洲的大部分天然气贸易崩溃,只有匈牙利、斯洛伐克、塞尔维亚和土耳其等少数国家继续通过管道接收天然气供应。 报告援引俄罗斯天然气工业股份公司(Gazprom)的数据称,俄罗斯已通过“西伯利亚力量”管道增加对中国的天然气输送量。该管道将于2025年达到380亿立方米的满负荷输送能力,而目前的输送量略高于该水平。 报告称,在与中国石油天然气集团公司达成新协议和基础设施扩建的支持下,预计到2029年,俄罗斯向东出口的天然气将攀升至约525亿立方米。 与此同时,报告补充说,预计到2028-2029年,俄罗斯通过管道向欧洲输送的天然气量将从今年的360亿立方米降至每年约320亿立方米。 报告称,在2022年入侵之前,俄罗斯天然气工业股份公司(Gazprom)每年向众多欧洲客户供应高达2000亿立方米的天然气。已联系俄罗斯天然气工业股份公司寻求置评。 (市场闲谈新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源,但可能包含传闻和推测。准确性无法保证。)
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.